arrow
G

Georgia M. Beasley

duke university
H指数:32
被引数:3,057

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma

III期FOCUS研究中,关于美法仑/肝内递送系统在不可切除性转移性葡萄膜黑色素瘤患者中的亚组分析

2025-12-290
OAAI
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma

不可切除的转移性葡萄膜黑色素瘤患者美法仑/肝递送系统与最佳替代护理的开放标签,随机研究

2025-04-010
OAAI
ASO Visual Abstract: Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-Institutional Cohort
2024-12-110
PRE
Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort

在多机构队列中,健康的社会决定因素对黑色素瘤结节监测的影响

2024-11-220
OAAI
Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab

来自IGNYTE临床试验中RP1联合nivolumab治疗组的、抗PD-1治疗失败的黑色素瘤患者注册意向队列的初步有效性、安全性和生存数据

2024-09-012
PRE
Subgroup analysis of FOCUS phase III trial efficacy results

FOCUS III期试验疗效结果的亚组分析

2024-09-010
PRE
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study (vol 31, pg 5340, 2024)
2024-07-180
OAAI
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
2024-05-240
PRE
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
2024-05-049
OAAI